Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
Pulmonary TB can be cured with shorter treatment, study finds

New data analysis uses precision medicine approach to demonstrate treatment efficacy. When patients were retrospectively stratified into minimal, moderate and severe disease categories, the four-month drug regimens turned out to have been highly effective for the 47 percent of patients with minimal disease. But the four-month regimens were not effective for patients with moderate or severe disease. And even the standard six-month treatment was insufficient for those with the most extensive disease.

Published
06 November 2018
From
Eurekalert Inf Dis
49th Union World Conference on Lung Health: 90 percent of participants in short-course XDR-TB regimen cured after six months

New results from the ongoing Nix-TB trial continue to confirm a short-course treatment regimen of bedaquiline – one of the two newest drugs to treat TB in half a century – linezolid and pretomanid offers a significantly improved treatment option for people infected with drug resistant forms of tuberculosis, researchers said here.

Published
05 November 2018
From
Science Speaks
49th Union World Conference on Lung Health: Integrating HIV treatment and TB preventative therapy greatly improves IPT adherence

When tuberculosis preventive therapy is delivered with HIV treatment services and patients get a choice in where they access treatment, completion of tuberculosis preventive therapy rises, helping to ensure people living with HIV stay healthy, researchers said here. This model of prevention should be scaled up in TB-HIV high burden settings, researchers said.

Published
05 November 2018
From
Science Speaks
49th Union World Conference on Lung Health: First promising TB vaccine candidate in 100 years needs more resources, researchers say

It's taken 100 years to see any progress in the development of a vaccine to prevent tuberculosis, a disease that kills 4,000 every day, Lucica Ditiu, executive director of the Stop TB Partnership said here. Even now, it remains uncertain that a new vaccine will see the light of day, she said, as more funding has yet to be secured for larger-scale trials to confirm the promising results of the M72 vaccine candidate.

Published
29 October 2018
From
Science Speaks
Bedaquiline price protests hit World Lung Conference launch

As the opening ceremony of the 49th Union World Conference on Lung Health kicked off in the Netherlands last night, protesting activists demanded Johnson & Johnson (J&J) slash its price for the blockbuster tuberculosis (TB) drug, bedaquiline.

Published
26 October 2018
From
Health-e
Johnson & Johnson prices keep key TB medicines out of reach

As US pharmaceutical corporation Johnson & Johnson (J&J) continues to charge high prices for its newer tuberculosis (TB) drug bedaquiline, people with drug-resistant tuberculosis (DR-TB) are forced to go without the best possible treatments, according to a new report—DR-TB Drugs Under the Microscope—released today by Doctors Without Borders/Médecins Sans Frontières (MSF) at the 49th Union World Conference on Lung Health in The Hague. J&J should cut the price of bedaquiline in half so more lives can be saved, said the international medical humanitarian organization MSF.

Published
23 October 2018
From
MSF
DR-TB Drugs Under the Microscope, 5th Edition

The 5th edition of “DR-TB Drugs Under the Microscope” chronicles the changing landscape of available treatments for DR-TB, outlines the key barriers to accessing the most effective treatments, and makes recommendations for action that can improve TB care on a global scale.

Published
23 October 2018
From
MSF
TB vaccine halves risk of disease in people with latent TB

A vaccine against tuberculosis (TB) reduced the risk of developing active TB in HIV-negative people with latent TB infection by 54% in a large phase 2b study

Published
10 October 2018
By
Keith Alcorn
One in five exposed to TB during HIV clinic visits, Malawi study finds

As many as one in five people attending an HIV clinic in Malawi had prolonged exposure to another patient with potentially infectious tuberculosis (TB) during the

Published
01 October 2018
By
Keith Alcorn
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study

Today, GSK and Aeras reported that GSK’s M72/AS01E[1] candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection[2] in an ongoing phase IIb clinical trial testing. These primary results published in the New England Journal of Medicine after two years of trial demonstrate an overall vaccine efficacy of 54%, with varied response rates observed in different demographic sub-groups.

Published
26 September 2018
From
Aeras
← First12345...111Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.